Pyxis Seeks to Double Authorized Shares to 380M So Its 49.3M Warrants Can Be Exercised
PYXS sits 74% above its 52-week low of $1.03 on light trading volume (0.4× avg).
Summary
Pyxis is asking shareholders on November 13 to double authorized common stock to 380M shares, because it cannot currently honor exercise of the 49.3M warrants sold in its October 1 offering. Approval also hands the board a large pool of shares for future raises.
Key Events · Corporate Governance and Compliance · PYXS
-
Authorized Shares Would Double to 380M
The charter amendment raises authorized common stock from 190,000,000 to 380,000,000 shares, while preferred stays at 10,000,000. Shareholders vote at the special meeting on November 13, 2026.
-
Warrants Unexercisable Without Approval
The 49,310,352 common warrants sold in the October 1, 2026 offering cannot be exercised because the company lacks authorized but unissued shares. According to the filing, if the amendment fails, the warrants will not be exercisable and may have no value.
-
Only 27.6M Shares of Headroom Today
Of 190,000,000 authorized shares, 119,583,637 are outstanding, 39,698,811 are reserved for options, RSUs and warrants, and 3,072,366 for future equity plan awards, leaving roughly 27,645,186 unissued and unreserved.
-
Repeat Meetings Every 60 Days if Rejected
Pyxis committed to call additional stockholder meetings every 60 days until approval is obtained or the warrants are no longer outstanding.
Analysis · PYXS · Life Sciences
The offering that closed October 1, 2026 included 36.0M shares, pre-funded warrants and 49.3M common warrants, and Pyxis lacks enough authorized stock to let those warrants be exercised. Without the charter amendment, the warrants are dead paper, which would gut the economics of the $110M raise and leave warrant holders with a claim the company cannot honor. The vote is set for November 13, 2026, and management has committed to repeat meetings every 60 days until it passes. Approval takes authorized common from 190M to 380M against 119.6M outstanding, giving the board broad discretion to issue stock for future financings. For a clinical-stage company with a going-concern warning and a $25.3M quarterly loss, that discretion will likely be used.
How filings like this one have moved
In the 30 days to Oct 22, 2026, 29.4% of the 1563 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PYXS was trading at $1.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $210.5M. The 52-week trading range was $1.03 to $5.55. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.